COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Use of Perioperative Antibiotics in Endoscopic Sinus Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03369717
Recruitment Status : Recruiting
First Posted : December 12, 2017
Last Update Posted : March 4, 2020
Information provided by (Responsible Party):
Nadeem Akbar, Montefiore Medical Center

Brief Summary:
The objective of this study is to determine whether the use of postoperative antibiotics following ESS decreases postoperative infection rates. This is a multi-institutional prospective study involving Albert Einstein College of Medicine/Montefiore Medical Center, Columbia University Medical Center, Weill Cornell Medical College, Mount Sinai Health System, and New York University Langone Medical Center. The study design will be a multi-institutional prospective randomized controlled trial with parallel random groups assigned to receive postoperative antibiotics or no postoperative antibiotics. The investigators hypothesize that patients who receive postoperative antibiotics will have lower postoperative infection rates and improved postoperative sinonasal symptoms and nasal endoscopy scores.

Condition or disease Intervention/treatment Phase
Chronic Sinus Infection Drug: Amoxi Clavulanate Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Use of Perioperative Antibiotics in Endoscopic Sinus Surgery
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Antibiotics
To receive postoperative antibiotics
Drug: Amoxi Clavulanate
Postoperative antibiotics

No Intervention: No antibiotics
Will not receive any postoperative antibiotics

Primary Outcome Measures :
  1. Decrease in postoperative infection [ Time Frame: 8 weeks ]
  2. Improvement in postoperative endoscopy scores [ Time Frame: 8 weeks ]
  3. Improvement in postoperative SNOT-22 scores [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients with CRS with or without nasal polyposis or allergic fungal rhinosinusitis who present to the otolaryngology clinic who have been deemed suitable for bilateral ESS, and are over the age of 18 will be included.

Exclusion Criteria:

  • Patients with sinonasal tumors, allergies or adverse reactions to all of the antibiotics that will be used in this study (amoxicillin-clavulanate, doxycycline, clarithromycin), immunodeficiency, cystic fibrosis, pregnancy, or diabetes with nasal polyposis (inability to receive systemic steroids) will be excluded, as will patients who lack capacity to provide informed consent. Patients undergoing active treatment for malignancy will be excluded. Patients undergoing unilateral ESS or with nonabsorbable packing placed at the time of surgery will be excluded. Patients who have been on antibiotics within 2 weeks of the surgery date will be excluded. Patients with acute on chronic sinusitis or the presence of purulence at time of surgery will be excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03369717

Layout table for location contacts
Contact: Nadeem A Akbar, MD 7189204646

Layout table for location information
United States, New York
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10467
Contact: Nadeem A Akbar, MD         
Sponsors and Collaborators
Montefiore Medical Center
Layout table for investigator information
Principal Investigator: Nadeem Akbar, MD Assistant Professor
Layout table for additonal information
Responsible Party: Nadeem Akbar, Assistant Professor, Montefiore Medical Center Identifier: NCT03369717    
Other Study ID Numbers: 2017-8460
First Posted: December 12, 2017    Key Record Dates
Last Update Posted: March 4, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Nadeem Akbar, Montefiore Medical Center:
endoscopic sinus surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Clavulanic Acid
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acids
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents